Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors.
Toni K. Choueiri
Consultant or Advisory Role - AVEO; Genentech; GlaxoSmithKline; Novartis; Novartis; Pfizer
Youjin Je
No relevant relationships to disclose
Guru Sonpavde
Consultant or Advisory Role - GlaxoSmithKline; Novartis
Honoraria - Novartis
Matt D. Galsky
No relevant relationships to disclose
Marina Kaymakcalan
No relevant relationships to disclose
Paul Linh Nguyen
No relevant relationships to disclose
Fabio Schutz
No relevant relationships to disclose
Daniel Yick Chin Heng
Consultant or Advisory Role - Novartis; Pfizer
Christopher J. Richards
No relevant relationships to disclose